Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An update meta-analysis of double-blind, randomized, placebo-controlled trials

International Journal of Neuropsychopharmacology

Volumn 18, Issue 9, 2015, Pages 1-11

  Dold, Markus ^a   Aigner, Martin ^b   Lanzenberger, Rupert ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b General Hospital Tulln   (Austria)

Author keywords

Antipsychotics; Meta analysis; Obsessive compulsive disorder; Serotonin reuptake inhibitors; Treatment resistance

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EFFECT SIZE; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS; MONOTHERAPY; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TIC; YALE BROWN OBSESSIVE COMPULSIVE SCALE; ADULT; DRUG POTENTIATION; FEMALE; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIPSYCHOTIC AGENTS; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 84941600299     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv047     Document Type: Review

References (51)

1. Baldwin DS, Anderson IM, Nutt D.J., Allgulander C., Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N., Malizia A, McCrone P, Nabarro D., O'Neill C, Scott J, van der Wee N, Wittchen HU (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Clin Psychopharmacol 28:403-439.
2. Bandelow B (2008) The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 13:37-46.
3. Bandelow B, Zohar J, Hollander E., Kasper S, Möller HJ (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 9:248-312.
4. Bandelow B, Sher L, Bunevicius R., Hollander E, Kasper S, Zohar J., Moller HJ, WFSBP Task Force on Anxiety Disorders, OCD, and PTSD (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16:77-84.
5. Bloch MH, Landeros-Weisenberger A, Kelmendi B., Coric V, Bracken MB, Leckman J.F. (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessivecompulsive disorder. Mol Psychiatry 11:622-632.
6. Borenstein M, Hedges LV, Higgins JPT, Rothstein H. (2006) Comprehensive meta-analysis, version 2. Englewood, New York: Biostat.
7. Bystritsky A, Ackerman DL, Rosen R.M., Vapnik T., Gorbis E, Maidment KM, Saxena S. (2004) Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 65:565-568.
8. Carey PD, Vythilingum B, Seedat S., Muller JE, van Ameringen M, Stein D.J. (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry 5:5.
9. Comer JS, Mojtabai R, Olfson M. (2011) National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatr 168:1057-1065.
10. Denys D, de Geus F, van Megen HJ, Westenberg H.G. (2004) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
11. Der-Simonian R., Laird N. (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
12. Diniz JB, Shavitt RG, Fossaluza V, Koran L., Pereira CA, Miguel E.C. (2011) A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacology 31:763-768.
13. Dold M, Aigner M, Lanzenberger R., Kasper S. (2013) Antipsychotic augmentation of serotonin reuptake inhibitors in treatmentresistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 16:557-574.
14. Ducasse D, Boyer L, Michel P., Loundou A, Macgregor A, Micoulaud-Franchi JA, Courtet P., Abbar M, Leboyer M, Fond G. (2014) D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacol 231:3765-3770.
15. Egger M, Davey Smith G, Schneider M, Minder C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
16. Erzegovesi S, Guglielmo E, Siliprandi F., Bellodi L. (2005) Lowdose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 15:69-74.
17. Fineberg NA, Sivakumaran T, Roberts A., Gale T. (2005) Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 20:223-226.
18. Fineberg NA, Reghunandanan S, Brown A., Pampaloni I. (2013) Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry 47:121-141.
19. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini R.J. (2010) International consensus study of antipsychotic dosing. Am J Psychiatr 167:686-693.
20. Goodman WK, Price LH, Rasmussen S.A., Mazure C., Fleischmann RL, Hill CL, Heninger GR, Charney D.S. (1989) Yale-Brown Obsessive-Compulsive Scale I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
21. Higgins JPT, Green S. (2011) Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, available from www.cochrane-handbook.org.
22. Hollander E, Baldini Rossi N, Sood E, Pallanti S. (2003) Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 6:397-401.
23. Kahn RS, Fleischhacker WW, Boter H, Davidson M., Vergouwe Y, Keet IP, Gheorghe M.D., Rybakowski JK, Galderisi S, Libiger J, Hummer M., Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J., Lindefors N, Riecher-Rossler A, Grobbee DE, EUFEST study group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085-1097.
24. Koran LM, Simpson H.B. (2013) Guideline watch (March 2013): practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association.
25. Kordon A, Wahl K, Koch N., Zurowski B, Anlauf M, Vielhaber K., Kahl KG, Broocks A, Voderholzer U, Hohagen F. (2008) Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 28:550-554.
26. Leucht S, Hierl S, Kissling W., Dold M, Davis J.M. (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 200:97-106.
27. Lieberman JA, Stroup TS, McEvoy J.P., Swartz MS, Rosenheck RA, Perkins DO, Keefe R.S., Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao J.K., Clinical Antipsychotic Trials of Intervention Effectiveness Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
28. Maina G, Pessina E, Albert U., Bogetto F. (2008) 8-week, singleblind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 18:364-372.
29. McDougle CJ, Goodman WK, Leckman J.F., Lee NC, Heninger GR, Price L.H. (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebocontrolled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
30. McDougle CJ, Epperson CN, Pelton G.H., Wasylink S., Price L.H. (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessivecompulsive disorder. Arch Gen Psychiatry 57:794-801.
31. Metin O, Yazici K, Tot S., Yazici A.E. (2003) Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 18:463-467.
32. Miodownik C, Bergman J, Lerner P.P., Kreinin A., Lerner V. (2015) Amisulpride as add-on treatment for resistant obsessivecompulsive disorder: retrospective case series. Clin Neuropharmacol 38:26-29.
33. Moher D, Liberati A, Tetzlaff J., Altman DG, Group P. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535.
34. Muscatello MR, Bruno A, Pandolfo G., Mico U, Scimeca G, Romeo V.M., Santoro V., Settineri S, Spina E, Zoccali R.A. (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 31:174-179.
35. Orwin R (1983) A fail-safe N for effect-size in meta-analysis. J Stat Educ 8:157-159.
36. Pallanti S, Quercioli L. (2006) Treatment-refractory obsessivecompulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 30:400-412.
37. Pallanti S, Hollander E. (2014) Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectr 19:50-61.
38. Sayyah M, Sayyah M, Boostani H., Ghaffari SM, Hoseini A. (2012) Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety 29:850-854.
39. Schirmbeck F, Zink M. (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10:88-95.
40. Schirmbeck F, Rausch F, Englisch S., Eifler S, Esslinger C, Meyer-Lindenberg A, Zink M. (2013) Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study. Schizophr Bull 39:1261-1271.
41. Selvi Y, Atli A, Aydin A., Besiroglu L, Ozdemir P, Ozdemir O. (2011) The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol 26:51-57.
42. Sesia T, Bizup B, Grace A.A. (2013) Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity. Int J Neuropsychopharmacol 16:1295-1307.
43. Shapira NA, Ward HE, Mandoki M, Murphy T.K., Yang MC, Blier P, Goodman W.K. (2004) A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 55: 553-555.
44. Simpson HB, Foa EB, Liebowitz M.R., Huppert JD, Cahill S, Maher MJ, McLean C.P., Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D., Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P., Hahn CG, Campeas R (2013) Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry 70:1190-1199.
45. Skapinakis P, Papatheodorou T, Mavreas V. (2007) Antipsychotic augmentation of serotonergic antidepressants in treatmentresistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17:79-93.
46. Soomro GM, Altman D, Rajagopal S., Oakley-Browne M (2008) Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev: CD001765.
47. Storch EA, Goddard AW, Grant J.E., De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B., McDougle CJ, Murphy T.K. (2013) Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitorresistant obsessive-compulsive disorder. J Clin Psychiatry 74:e527-532.
48. The Cochrane Collaboration (2014) Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre.
49. Van Ameringen M., Simpson W, Patterson B., Dell'Osso B, Fineberg N, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, Pallanti S, Stein DJ, Zohar J (2014) Pharmacological treatment strategies in obsessive compulsive disorder: a cross-sectional view in nine international OCD centers. J Psychopharmacol 28:596-602.
50. Vulink NC, Denys D, Fluitman S.B., Meinardi JC, Westenberg H.G. (2009) Quetiapine augments the effect of citalopram in nonrefractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry 70:1001-1008.
51. Zink M, Schirmbeck F, Rausch F., Eifler S, Elkin H, Solojenkina X., Englisch S, Wagner M, Maier W., Lautenschlager M, Heinz A, Gudlowski Y., Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Juckel G, Krueger-Oezguerdal S, et al. (2014) Obsessive-compulsive symptoms in at-risk mental states for psychosis: associations with clinical impairment and cognitive function. Acta Psychiatr Scand 130:214-226.